Biotech | September 26, 2021
U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations
The company does not expect the outcome of this inspection to impact its plans
The company does not expect the outcome of this inspection to impact its plans
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Medical experts point to a growing body of research linking energy drinks to liver injury
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Panacea Biotec receives LoA from CMSS
This inspection is now closed
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Subscribe To Our Newsletter & Stay Updated
